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vivo. PET tracers are usually administered at a negligible dose
without inducing any pharmacological effect. Non-invasive PET
imaging can provide information pertaining to target localization
and density changes in pathologic conditions, and has proven to
be a powerful technique in neurological research.[2] Carbon-11
and fluorine-18 are two commonly used PET radionuclides for
imaging the CNS due to their chemical properties and suitable
physical half-lives of 20 min and 110 min, respectively. Criteria
for a successful CNS PET tracer are:
· The ligand should be amenable for C-11 or F-18 incorporation.
In general, late-stage radiolabeling approaches are favored.
· It should provide strong affinity towards the target (K
D
in the
low nanomolar to subnanomolar range depending on the con-
centration of target sites B
max










, the higher the signal-to-noise ratio.[3]





should be more than 100-fold higher than for other potential
targets.
· It should provide good permeability of the blood-brain barrier
(BBB); the logarithmic partition coefficient (log P) of CNS
PET tracers should be well above 1 to allow their passage
across the BBB, but still displaying low nonspecific binding
to reduce the signal-to-noise ratio.[4] The recommended log P
range for CNS PET tracers is 1 to 3.5.[5]
· It should not be a substrate for BBB efflux transport systems;
the BBB possesses efflux pumps which can prevent com-
pounds from effectively distributing to the brain, of which
P-glycoprotein (P-gp) is a key efflux pump.[6] Therefore, a
PET tracer should not be a substrate for BBB efflux systems.
· Absence of brain-penetrant radiometabolites; radiometabolites
should not be able to cross the BBB as they would increase
non-specific signals in the brain and complicate quantification.
Besides the above-mentioned criteria, intra- and inter-subject
variability should be also considered before clinical translation, as
higher variability requires larger sample size studies to delineate
alterations between populations.
It should be pointed out that these criteria are recommended
guidelines to assist in the selection of potential CNS imaging li-
gands. They provide no guarantee for the successful development
of a PET tracer. Therefore, recently, multiparameter optimization
(MPO)hasbeenapplied in screeningCNSdrugsandPETtracers.[7]
The additional physico-chemical parameters to be taken into
consideration for optimization include lipophilicity, molecular
weight, topological polar surface area, number of hydrogen bond
donors and pKa value of a substance.
1.2 Synthesis of Carbon-11 and Fluorine-18 Labeled
Tracers
Among the many available positron emitting radionuclides,
carbon-11 and fluorine-18 are the most often used radioisotopes
for brain imaging (Scheme 1). In our laboratory, [11C]CO
2
or [18F]
fluoride can be produced using a Cyclone 18/9 cyclotron (18-MeV;
IBA, Belgium) by proton bombardment of a nitrogen gas target
(14N(p, α)11C nuclear reaction) or oxygen-18 enriched water tar-
get (18O(p, n)18F nuclear reaction), respectively.[8] The simplest and
most widely used method for introducing carbon-11 into a pharma-
ceutical compound is via radiomethylation of an appropriate pre-
cursor compound.[9] For that, [11C]iodomethane ([11C]MeI) can be





catalyst and subsequent gas phase iodination at high temperature
(720 °C). For synthetically challengingmethylation reactions, [11C]
MeI can be converted to the more reactive [11C]methyl triflate.
The cyclotron-produced [18F]fluoride is in its aqueous form
highly hydrated. Therefore, water is usually first removed through
trapping the fluoride on an anion exchange cartridge (QMA
cartridge) and subsequent elution using potassium carbonate
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1. Introduction
The ETH site of the Center for Radiopharmaceutical Sciences
(CRS) was set up in 2005. It comprises a cyclotron for radio-
nuclide production, several lead-shielded hoods equipped with
manipulators and automated modules in radiolabeling labs for
pre-clinical and GMP synthesis, organic chemistry labs, animal
facilities and PET/CT scanners for preclinical imaging. Ongoing
research activities include target identification, lead finding and
optimization, structure–activity relationship studies, radiolabeling
with C-11 and F-18. The radiotracer evaluation covers metabolic
studies, in vitro autoradiography, in vivo PET imaging and kinetic
modelling. The GMP labs enable clinical studies using novel PET
tracers, which were developed at CRS or by our academic and in-
dustry partners. Much emphasis is devoted to the development of
novel PET tracers for molecular imaging receptors, transporters
and enzymes, which have implications in neurology, cardiology
and oncology. In the past years PET tracers targeting the glu-
tamatergic system, namely the metabotropic glutamate receptor
subtype 5 (mGluR5) and GluN2B subunit N-methyl-d-aspartate
(NMDA) receptor have been developed.[1] This review paper pro-
vides a short summary on our research activities on targeting these
two central nervous system (CNS) receptors.
1.1 Positron Emission Tomography Tracer
Development for the Central Nervous System
Positron emission tomography (PET) is a non-invasive,
quantitative, nuclear medicine imaging technique, which em-
ploys radiation from positron emitting radioisotopes to produce
a three-dimensional image of the distribution of radiotracers in
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As such, this receptor is considered as a potential drug target for
the treatment of the aforementioned CNS disorders. A number
of noncompetitive mGluR5 ligands have been developed during
the past years. 2-Methyl-6-(phenylethynyl)pyridine (MPEP) and
3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) are the
first potent and selective noncompetitive mGluR5 antagonists.[12]
Many succeeding compounds have been developed based on the
core structures of MPEP and MTEP. The relatively high expres-
sion levels of mGluR5 in distinct brain regions (e.g. hippocampus,
striatum, amygdala, and cortex) and the availability of high affin-
ity ligands render this protein a good target for PET imaging. [11C]
ABP688 is the first successful PET tracer for imaging mGluR5 in
human subjects.[13] The radioactivity distribution pattern was in
line with the mGluR5 expression levels in the human brain men-
tioned above. Using [11C]ABP688, downregulation of mGluR5
has been demonstrated in the brains of smokers and patients suf-
fering from depression,[14] while sleep-deprived subjects showed
a global increase in mGluR5 availability when compared to nor-
mal healthy controls.[15] More studies are planned in patients with
Parkinson’s disease, multiple sclerosis and epilepsy. Although
[11C]ABP688 was employed in many clinical studies because of
its superior pharmacokinetic characteristics, its widespread use is
limited due to the short physical half-life of carbon-11 (t
1/2
= 20
min). This prompted us to develop a fluorine-18 labeled analogue
which allows distribution of the radiotracer to PET centers lack-
ing an on-site cyclotron. This article provides a summary of our
efforts towards the development of fluorine-18 labeled mGluR5
PET tracers and their in vitro and in vivo evaluations (Fig. 1).
2.1 Replace Methyl Group with Fluorine Atom of the
Pyridine Ring




2-yl)ethynyl)cyclohex-2-enone O-methyl oxime in dry DMSO.
Despite all the promising in vitro results of optimal lipophilicity
(logD=2.1), a K
i
value of 3.6 nM and high activity accumula-
tion in mGluR5-rich rat brain regions, a rapid defluorination was
observed in rat brain in vivo. Further studies with this tracer were
consequently abandoned (Fig. 1).[16]
2.2 Replace Hydrogen by Fluorine Atom on the
Cyclohexane Ring
Among five synthesized ABP688 derivatives with fluorine





) in the presence of Kryptofix 222 (K
222
) or tetra-butylam-
monium hydroxide to form [18F]KF-K
222
or [18F]TBAF, respec-
tively. Further azeotropic drying with acetonitrile affords ‘naked’
fluoride, which displays increased nucleophilicity and can be used
in various alkyl and aromatic nucleophilic substitution reactions.
Radiolabeling of electron-rich aromatic rings can be facilitated by
copper-mediated fluorination of pinacol boronic ester.[10]
1.3 Targeting Glutamatergic System with PET
Glutamate is the major excitatory neurotransmitter in the
mammalian CNS, and glutamate receptors (GluR) are impli-
cated in a range of neurological functions. Two distinct groups
of GluRs have been identified: ionotropic receptors (iGluR) and
metabotropic receptors (mGluR). The vast majority of excitatory
neurotransmission is mediated via ligand-gated iGluR of which
three major types are currently well-characterized, namely the
α-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid (AMPA),
N-methyl-d-aspartate (NMDA) and the kainate receptors. mGluR
belong to the superfamily of G-protein-coupled receptors and in-
clude eight receptor subtypes, classified into three groups. Group
I includes mGluR1 and mGluR5, group II includes mGluR2 and
mGluR3, and group III includes mGluR4, mGluR6, mGluR7, and
mGluR8. Modulation of iGluR and mGluR has potential for the
treatment of psychiatric and neurological diseases such as depres-
sion, anxiety, schizophrenia, and Parkinson’s disease. PET im-
aging of glutamate receptors can provide essential information
on the function of individual receptors and their variation under
physiologic, pathologic and therapeutic conditions. CRS at ETH
has worked since many years on the development of radioligands
for mGluR5 and GluN2B subunit of the NMDA receptors. Two
mGluR5 PET tracers, [11C]ABP688 and [18F]PSS232, have been
evaluated in human subjects, and novel GluN2B PET tracers are
on the way to be translated into first-in-human studies (see below).
2. Metabotropic Glutamate Receptor Subtype 5
(mGluR5)
The mGluR5 belongs to group I of metabotropic glutamate
receptors. It plays a key role in long-term potentiation and in-
creasing evidence indicated that it might be involved in numer-
ous CNS disorders including depression, anxiety, addiction,
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Scheme 1. Synthetic schemes of 11C- and 18F-labeled radiopharmaceu-
ticals for targeting the mGluR5 ([11C]ABP688 and [18F]PSS232) and the








































Fig. 1. Strategies to develop F-18 labeled ABP688 analogues.
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oxygen atom located between the ethylene and the fluoropropyl
moieties with the CH
2
group of the right side of [18F]PSS223 (Fig.
1) gave rise to [18F]PSS232. [18F]PSS232 revealed improved in
vitro and in vivo stabilities.[1e,24] The specificity of [18F]PSS232
was confirmed in in vitro autoradiography on rat brain slices
and in vivo PET images. [18F]PSS232 turned out to be an ideal
F-18 labeled PET tracer for imaging mGluR5 in rat brain (Fig.
2). Image data were reproducible in test–retest studies with a
variability ranging from 6.8% to 8.2%. An extended single-dose
toxicity study in Wistar rats showed no compound-related toxic
effects.[1e] Encouraged by the promising preclinical data obtained
with [18F]PSS232 in rodents, the radiochemistry was established
in our GMP labs, and the results of first-in-human studies were
published in 2018.[1f]The brain uptake pattern of [18F]PSS232 was
similar to that of its analog [11C]ABP688, and matched the distri-
bution pattern of mGluR5. The kinetics of [18F]PSS232 followed
a two-tissue compartment model, as seen for many neuroreceptor
PET tracers.We hope that this new fluorinated version ofABP688
will find a wider application in clinical studies in the near future.
Initial studies using [18F]PSS232 to measure mGluR5 expression
levels in LPS-induced murine neuroinflammation model showed
increased mGluR5 expression in neuroinflammatory mouse
brain.[25] In autoradiographic studies, levels of mGluR5 in human
AD and amyotrophic lateral sclerosis (ALS) postmortem brain
were also found to be several-fold higher compared to control
brains.[25] These results suggest that mGluR5 might be a useful
target to consider for neuroinflammatory diseases and that diag-
nosis and the therapy monitoring of AD and ALS patients could
be accomplished via mGluR5 imaging.
3. GluN2B Subunit of the N-Methyl-d-aspartate
Receptor
The NMDA receptor is one of three glutamatergic ion chan-
nel types that are ubiquitously expressed in the CNS, and are
requisite in synaptic transmission, plasticity and higher cognitive
functions.[26] NMDA receptors are heterotetrameric assemblies
of three distinct subunits, namely GluN1-3. The identity of these
subunits are further complexed by splice variants (GluN1a-h)
and different encoding genes (GluN2A-D and GluN3A-B). For
NMDA to be fully functional, it requires the obligatory presence
of two GluN1 subunits in addition to two GluN2 or GluN3 sub-
units.[27] The presence of a particular GluN2 subunit governs the
functionof the receptorwithin aunique spatiotemporal expression
framework. Extrasynaptic GluN2B subunit-containing NMDA
receptor gathered much attention owing to their involvement in a
plethora of neurological pathologies such asAlzheimer’s disease,
Parkinson’s disease, depression, stroke and schizophrenia.[28]
Consequently, contemporary therapeutic targeting approaches
steered away from non-selective NMDA modulators, and fo-
cused on subunit-selective modulators, with GluN2B subunit-
containing NMDA receptor being the most exploited. In paral-
oxime ether (Z)-FABP688, which not only showed a desired K
i
value of 5.7 nM but also a clogP of 2.3, was selected for radiola-
beling with F-18. However, the synthesis of the tosylate precur-
sor for radiolabeling revealed a stereochemical preference for the
E-isomer of the α-hydroxy derivative which prompted us to pre-
pare (E)-[18F]FABP688 (Fig.1). The K
i
value for this compound
was determined as 31 nM, which is ca. 6-fold less potent than its
Z-form. Although specific signal was observed in in vitro autora-
diography studies,[17] the suboptimal affinity and the challenging
chemistry prevented further evaluation on this type of structure.
2.3 Replace the Methyl Group of Oxime Ether with
Fluorinated Alkyl Chain
FE-DABP688 was obtained by replacing the methyl group of
oxime ether with fluoroethyl and exhibited a K
D
value of 1.6 nM.
Although the obtained PET image quality of [18F]FE-DABP688
was similar to that of [11C]ABP688, [18F]FE-DABP688 displayed
unfavorable pharmacokinetics in the anesthetized rat with a fast
washout from the forebrain resulting in a relatively short-lived
signal.[18] Consequently, [18F]FE-DABP688 was not exploited
further (Fig. 1).
Changing the methyl group at the oxime functionality by
different fluorinated aromatic substituents resulted in moderate
binding affinities towards mGluR5.[19] Therefore, more efforts
were placed on the synthesis of fluorinated alkyl ABP688 deriva-
tives. Prolongation of the alkyl linker of FE-DABP688 resulted in
three compounds named FDEGPECO, PSS223 and PSS232 (Fig.
1). All of them revealed high affinity towards mGluR5, indicat-
ing alkyl substituents at the oxime functionality are well tolerated
(Fig. 2). [18F]FDEGPECO was produced in a single high-yielding
radiochemical step. Target specificity was confirmed by in vitro
autoradiography and in vivo PET studies.[20]Although quantifica-
tion of mGluR5 was possible, image quality suffered from high
background radioactivity (Fig. 2).
PSS223 was designed with the aim to increase the lipophilic-
ity of the ligand, in which the side chain was extended by one
methylene group. The experimentally determined log D value of
[18F]PSS223 was 1.9, which is 0.2 log units higher than that of
[18F]FDEGPECO, as expected.[19,21] [18F]PSS223 showed a het-
erogeneous distribution on rat brain slices with the highest accu-
mulation in mGluR5-rich brain regions (e.g. hippocampus, stria-
tum, and cortex). Its specificity and selectivity towards mGluR5
was confirmed by using excess concentrations of mGluR5 and
mGluR1 blockers. However, [18F]PSS223 was significantly me-
tabolized by rat liver microsomal enzymes and to a lesser extent
by human liver microsomes. In vivo PET imaging showed high
radioactivity in the skull and jaws, and a weak accumulation in the
rat brain (Fig. 2),[21] indicating rapid [18F]defluorination in vivo.
Thedifference insusceptibility fordefluorinationbetween[18F]
PSS223 and [18F]FDEGPECO was attributed to the β-heteroatom





OR) are found to be more stable than
[11C]ABP688
Ki : 4.4 nM
log D: 2.4
[18F]FDEGPECO
Ki : 3.8 nM
log D: 1.7
[18F]PSS223
KD : 3.3 nM
log D: 1.9
[18F]PSS232
IC50 : 1.3 nM
log D: 2.0
0 2.50 2.5 0 2.5 0 4.5
Brain
Fig. 2. PET/CT images of [11C]
ABP688 and its fluorinated deriva-
tives [18F]FDEGPECO, [18F]PSS223
and [18F]PSS232 averaged from
0–40 min p.i. in rat brain (brain
region indicated by red circle).
Binding affinities were determined
by using rat brain membranes, for
compound PSS232, the IC50 value
was 1.1 nM for human mGluR5
using [3H]ABP688 as the radioli-
gand. Shake-flask method was
used to determine the distribution
coefficients (log D) at pH 7.4.
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lel, rigorous efforts have been made over the last two decades to
introduce a clinically validated PET tracer for imaging GluN2B
subunit-containing NMDA receptor to no avail. Major challenges
comprised brain radiometabolites, considerable off-target bind-
ing, low brain uptake and brain uptake inconsistent with known
GluN2B expression profile.[29] Our group has been active in de-
veloping PET radioligands for imaging GluN2B subunit-contain-
ing NMDA receptor for almost a decade now. We have explored
the chemical space pertaining to 2,3,4,5-tetrahydro-1H-3-ben-
zazepine and 6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-amine
derivatives.[1a–d,g] These two classes were comprehensively in-
vestigated by Wünsch and co-workers as therapeutic agents.[30]
We utilized two key measures to perform preliminary screen-
ing of various compounds stemming out of these two classes.
One measure involves determining the affinity of the ligand in
question towards rat and/or human GluN2B subunit-containing
NMDA receptors using competitive binding assays. The second
measure utilizes the same approach to investigate the off-target
binding of the developed ligands, mainly towards sigma-1 recep-
tors (σ1Rs), and to a lesser extent σ2Rs. The σ1R is an endoplas-
mic reticulum-embedded, ligand-regulated molecular chaperone
that regulates the activity of NMDA.[31] Concomitantly, the σ1R
bears a binding site that is highly similar to the ifenprodil-binding
site at the interface of GluN2B and GluN1 subunits that confers
subunit-selectivity to GluN2B subunit targeting ligands. Such a
similarity further increases the magnitude of complexity asso-
ciated with the development of GluN2B PET imaging tracers.
The first benzazepine-based PET ligand reported by our group
for the imaging of GluN2B subunit-containing NMDA receptors
was [11C]Me-NB1, a 2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol
derivative (Fig. 3).[1g] In this preliminary breakthrough work,
Me-NB1 (K
i
(GluN2B) = 5.4 nM, K
i
(σ1R) = 182 nM, and K
i
(σ2R) = 554[30a]) was labeled with carbon-11 using [11C]MeI,
and investigated in in vitro autoradiographic experiments us-
ing brain slices from wild-type and σ1R-knockout mice. While
no significant differences were detected in tracer accumulation
between wild-type and σ1R-knockout brain slices, specificity
and selectivity of [11C]Me-NB1 binding were confirmed using
eliprodil, a GluN2B subunit-containing NMDA antagonist and
(+)-pentazocine, a σ1R ligand. Encouraged by these results, [11C]
Me-NB1 was evaluated in Wistar rats using PET, blocking and
displacement experiments as well as PET kinetic modeling. At
the time, (+)-pentazocine reduced the tracer brain uptake of [11C]
Me-NB1 thereby supporting the notion of σ1R-NMDA cross-
talk. In a later report from our group by Haider and co-workers,
it was revealed that a tightrope walk between GluN2B subunit-
containing NMDA receptors and σ1Rs affinities exists which is
heavily dictated by the enantiomeric form of [11C]Me-NB1.[1c] In
in vitro autoradiography, a heterogeneous accumulation of (R)-
[11C]Me-NB1 mirrored the known expression pattern of GluN2B
subunit-containing NMDA receptors in the forebrain regions
comprising the cortex, striatum, thalamus and hippocampus. The
specificity and selectivity were established by using a wider vari-
ety of GluN2B subunit-containing NMDA blockers (CERC-301,
EVT-101 and CP-101,606) and σ1R ligands (SA4503, fluspidine
and (+)-pentazocine). Importantly, (R)-[11C]Me-NB1 displayed
a consistent dose-response profile with escalating doses of elip-
rodil in vivo, whereas (S)-[11C]Me-NB1 exhibited specific bind-
ing predominantly towards σ1R. (R)-[11C]Me-NB1 is currently
being assessed in a first-in-human PET studies. Nonetheless,
the foremost inherent drawback of this tracer is the short physi-
cal half-life of carbon-11 (physical half-life = 20 min), which
hampers its utility in PET centers lacking an on-site cyclotron.
The development of a fluorine-18 (physical half-life = 110 min)
analogue would resolve the aforementioned drawback, thereby
realizing the satellite distribution concept, and simultaneously
offering higher image resolution.[32]
In 2018, we tackled this challenge and evaluated four differ-
ent fluorinated analogues by in vitro autoradiography.[1d] (R)-[18F]
OF-Me-NB1 emerged as the first fluorinated analogue from the
structural class of 2,3,4,5-tetrahydro-1H-3-benzazepin-1-ols for
imaging the GluN2B subunit. For the radiosynthesis of (R)-[18F]
OF-Me-NB1, we harnessed the copper-mediated radiofluori-
nation of boronic esters, followed by the cleavage of an acetyl
protecting group using basic conditions.[33] Later we performed
structure–affinity relationship studies and developed [18F]PF-
NB1. This tracer was evaluated in Wistar rats and σ1R-knockout
mice (Fig. 4).[1a]A remarkable characteristic of [18F]PF-NB1 is its
slow in vivo brain kinetics relative to earlier tracers. In most recent
work, we reported the ortho-analogue, [18F]OF-NB1, as the first-
in-class successor of [18F]PF-NB1, with higher uptake in GluN2B
subunit-containing NMDA-rich brain regions inWistar rats deter-
mined in ex vivo biodistribution studies. The potential of imaging
the GluN2B subunit was further assessed in cortical brain samples
fromALS patients and healthy controls via autoradiography stud-
ies.[1b] The presence of radiometabolites in the brain by means of
ex vivo metabolite studies could be excluded. Additionally, we
showed the utility of all the tracers through receptor occupancy
studies with the GluN2B subunit-containing NMDA antagonists,
eliprodil and CP-101,606. In collaboration with Yale University
PET Center, the (R)- and (S)-enantiomers of [18F]OF-NB1, [18F]
OF-Me-NB1 and [11C]Me-NB1 were assessed in non-human pri-
mates.[34] We are currently preparing the documents for a first-
in-human PET study. The successful outcome of this study will
allow us to validate the radioligand for imaging GluN2B subunit-
containing NMDA in different neuropathologies.
4. Quantification Methods, from SUV to Kinetic
Modeling
PET is a quantitative imaging method. The reconstructed im-
ages can directly be scaled to Bq/cm3. Normalization for the ad-





















































Fig. 3. Structures of developed fluorinated and non-fluorinated radio-
ligands based on the 2,3,4,5-tetrahydro-1H-3-benzazepine structural
class developed in our group. In the green boxes are highlighted the
most promising PET ligands that possess potential for clinical transla-
tion. (R)-[11C]Me-NB1 is currently being investigated in a first-in-human
PET study.
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depend on the interaction
between the tracer and its target and, importantly, k
3
on target




defines the distribution volume
between displaceable (specifically bound) and non-displaceable
assuming 1 g tissue corresponds to 1 cm3, reveals the SUV as a
dimensionless parameter. If the applied activity distributed evenly
throughout the organism and no activity was excreted the SUV
equals to 1. SUV is time-dependent as seen in Fig. 4C but can be
averaged over a defined time window to result in an individual
parameter, such as SUV averaged from 0 to 90 min after injec-
tion used in Fig. 4D. SUV not only depends on the target density
and availability for tracer binding, but on many additional factors.
These are in particular the kinetics of the tracer in blood plasma,
which depends on tracer distribution in the whole body, tracer
excretion, metabolism and binding to plasma proteins. The influ-
ence of these factors can be excluded by kinetic modeling with
the tracer plasma concentration-time curve, called input function.
Mechanistic models can be fitted to the input function and image
data. PET tracers for neuroreceptors often follow the two-tissue
compartment model shown in Fig. 5.
In the two-tissue compartment model shown in Fig. 5, K
1
rep-
resents the clearance term from plasma to tissue. It maximally
reaches the value of plasma (or blood) flow. Depending on the





equals the distribution volume (normalized to tissue
volume) of non-displaceable (nonspecifically distributed) tracer.








































3 mg/kg CP-101,6061 mg/kg CP-101,606
min max






Mid frame time (min)
SU
V
Baseline (n=3) 1 mg/kg CP-101,606 blockade
3 mg/kg CP-101,606 blockade 5 mg/kg CP-101,606 blockade
10 mg/kg CP-101,606 blockade
Fig. 4. Typical in vitro autoradiograms, baseline and blockade PET images, whole brain time-activity curves and receptor occupancy plot of one of
the promising radiofluorinated PET radioligands, [18F]PF-NB1, developed by our group for imaging the GluN2B subunit of the NMDA receptor. A) An
autoradiogram of [18F]PF-NB1 obtained from rat coronal brain sections where accumulation of the tracer is observed in GluN1/GluN2B rich regions
comprising cortex, hippocampus, striatum and thalamus. B) Baseline and blockade (10 mg/kg CP-101,606) in vivo PET images (30-90 min aver-
aged) of the Wistar rat brain superimposed on an MRI template (PMOD). The color bar denotes standardized uptake value (SUV). C) Corresponding
time-activity curves of [18F]PF-NB1 presented as SUV0-90 min under baseline and blockade conditions with escalating doses of the GluN1/GluN2B
antagonist CP-101,606. D) Calculated from the SUV0-90 min, the receptor occupancy was plotted and the CP-101,606 dose required to occupy
50% of the receptors in vivo (D50) was found to be 31 µmol/kg. Adapted with permission from Ahmed et al. Journal of Medicinal Chemistry 2019.



























Fig. 5. Two-tissue compartment model for the kinetic analysis in neuro-
receptor PET.
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non-invasive characterization of numerous CNS disorders and the
determination of appropriate doses of drugs targeting the GluN2B
aswas similarly done for other establishedCNSPET radioligands.
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The recording of an input function requires an arterial catheter.
In preclinical imaging with rodents, we even apply an arteriove-
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counter. This invasive technique is not intended for routine scans
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(Fig. 5). The respective results can
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We performed kinetic modeling with [18F]PSS232 in rats[35]
and human volunteers[1f] and for [11C]Me-NB1 in rats.[1g] The
modeling with an arterial input function confirmed that tracer
activity in the brain follows two-tissue compartment models
for both tracers, independent of the species. Fig. 6 shows [18F]
PSS232 brain PET images of a volunteer. The upper row shows
the DVR, calculated with cerebellum as the reference tissue. DVR
is a robust parameter as any variability in blood radioactivity is
cancelled out as long as the region of interest and the reference
region have the same perfusion (same input function). DVR is,
therefore, frequently used in quantitative PET if a reference re-
gion can be defined.[14] The lower row in Fig. 6 shows the activity
averaged from 45–90 min (kBq/cm3), when distribution is equili-
brated (steady state is reached). As expected at steady state, the
averaged activity shows the same pattern as the DVR. However,
the absolute numbers (kBq/cm3) depend on the activity dose and
the chosen time window.
5. Conclusion
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NMDA receptor for human application. The ongoing preclinical
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90 min after tracer injection, when
tracer distribution is in steady
state. Adapted from Warnock et
al. European Journal of Nuclear
Medicine and Molecular Imaging
2018. Reprinted with the permis-
sion from Springer Nature and
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